THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS

Özlem Kandemir Alibakan; Hasan Eruzun; İlkim Deniz Toprak; Uğur Yılmaz; Mehmet Alptekin Acar; İpek Bilge Aslan; Merve Polat Onmaz; Yasemin Gökden; Yücel Arman; Tufan Tükek

Makale detayları

THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS

Yazarlar:

Özlem Kandemir Alibakan | Hasan Eruzun | İlkim Deniz Toprak | Uğur Yılmaz | Mehmet Alptekin Acar | İpek Bilge Aslan | Merve Polat Onmaz | Yasemin Gökden | Yücel Arman | Tufan Tükek

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.209-214

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001330648

pISSN:

1305-6441

Anahtar kelimeler:

Özet:

 Objective: Nesfatin-1 is an anorectic polypeptide that plays im portant roles in regulating appetite and energy intake. Cachexia and malnutrition are common in individuals with cirrhosis. We ex amined the relationship between serum nesfatin-1 levels and stage of cirrhosis, with the hypothesis that an increase in nesfatin-1 levels in patients with cirrhosis may be related to this catabolic process. Material and Method: The study includes 51 patients with cirrhosis and 30 healthy volunteers. Nesfatin-1 levels in serum samples were compared using the enzyme-linked immunosorbent assay ELISA. We calculated the Child-Pugh stages and Model for End-Stage Liver Disease MELD scores of patients with cirrhosis and examined their relationship with nesfatin-1. Weve also investigated the relationship between cirrhosis complications and nesfatin-1. Results: We found nesfatin-1 levels to be significantly higher in the cirrhosis patient group compared to the control group p0.001. The patient group was divided into those with compensated and those with decompensated liver cirrhosis and compared with the control group. Nesfatin-1 levels were found to be significantly higher in the compensated liver cirrhosis group p0.01. When classifying the patients with cirrhosis based on their Child-Pugh stages and MELD scores, no significant relationship was detected between these groups and their nesfatin-1 levels. Conclusion: Nesfatin-1 may have antioxidant, anti-inflammatory, and anti-apoptotic effects in maintaining the state of patients with compensated liver cirrhosis. Low levels of nesfatin-1 in decompensated liver cirrhosis may result from defense mecha nisms and inadequate production.

 Objective: Nesfatin-1 is an anorectic polypeptide that plays im portant roles in regulating appetite and energy intake. Cachexia and malnutrition are common in individuals with cirrhosis. We ex amined the relationship between serum nesfatin-1 levels and stage of cirrhosis, with the hypothesis that an increase in nesfatin-1 levels in patients with cirrhosis may be related to this catabolic process. Material and Method: The study includes 51 patients with cirrhosis and 30 healthy volunteers. Nesfatin-1 levels in serum samples were compared using the enzyme-linked immunosorbent assay ELISA. We calculated the Child-Pugh stages and Model for End-Stage Liver Disease MELD scores of patients with cirrhosis and examined their relationship with nesfatin-1. Weve also investigated the relationship between cirrhosis complications and nesfatin-1. Results: We found nesfatin-1 levels to be significantly higher in the cirrhosis patient group compared to the control group p0.001. The patient group was divided into those with compensated and those with decompensated liver cirrhosis and compared with the control group. Nesfatin-1 levels were found to be significantly higher in the compensated liver cirrhosis group p0.01. When classifying the patients with cirrhosis based on their Child-Pugh stages and MELD scores, no significant relationship was detected between these groups and their nesfatin-1 levels. Conclusion: Nesfatin-1 may have antioxidant, anti-inflammatory, and anti-apoptotic effects in maintaining the state of patients with compensated liver cirrhosis. Low levels of nesfatin-1 in decompensated liver cirrhosis may result from defense mecha nisms and inadequate production.

 Objective: Nesfatin-1 is an anorectic polypeptide that plays im portant roles in regulating appetite and energy intake. Cachexia and malnutrition are common in individuals with cirrhosis. We ex amined the relationship between serum nesfatin-1 levels and stage of cirrhosis, with the hypothesis that an increase in nesfatin-1 levels in patients with cirrhosis may be related to this catabolic process. Material and Method: The study includes 51 patients with cirrhosis and 30 healthy volunteers. Nesfatin-1 levels in serum samples were compared using the enzyme-linked immunosorbent assay ELISA. We calculated the Child-Pugh stages and Model for End-Stage Liver Disease MELD scores of patients with cirrhosis and examined their relationship with nesfatin-1. Weve also investigated the relationship between cirrhosis complications and nesfatin-1. Results: We found nesfatin-1 levels to be significantly higher in the cirrhosis patient group compared to the control group p0.001. The patient group was divided into those with compensated and those with decompensated liver cirrhosis and compared with the control group. Nesfatin-1 levels were found to be significantly higher in the compensated liver cirrhosis group p0.01. When classifying the patients with cirrhosis based on their Child-Pugh stages and MELD scores, no significant relationship was detected between these groups and their nesfatin-1 levels. Conclusion: Nesfatin-1 may have antioxidant, anti-inflammatory, and anti-apoptotic effects in maintaining the state of patients with compensated liver cirrhosis. Low levels of nesfatin-1 in decompensated liver cirrhosis may result from defense mecha nisms and inadequate production.

 Amaç: Nesfatin-1, iştahın ve enerji alımının düzenlenmesinde önemli rolleri olan anorektik bir polipeptittir. Kaşeksi ve malnut risyon sirozlu bireylerde yaygındır. Nesfatin-1 düzeylerinin siroz lu hastalardaki artışının sirozdaki katabolik süreçle alakalı olabi leceği hipoteziyle nesfatin-1 serum düzeyleri ve siroz aşamaları ilişkisini inceledik. Gereç ve Yöntem: Çalışmamıza 51 sirozlu hasta ve 30 sağlıklı gönüllü alındı. Serum örneklerinden nesfatin-1 düzeyleri ELISA kullanılarak karşılaştırıldı. Sirozlu hastaların Child-Pugh evreleri ve multifaktöriyel son dönem karaciğer hastalığı modeli MELD skorları hesaplanarak nesfatin-1 ile ilişkileri incelendi. Ek olarak siroz komplikasyonları ile nesfatin-1 arasındaki ilişki araştırıldı. Bulgular: Nesfatin-1 düzeyleri sirozlu hasta grubunda kontrol grubuna göre anlamlı olarak yüksek bulundu p0,001. Hasta grubu kompanse ve dekompanse olarak ayrılıp, kontrol grubu ile karşılaştırıldı. Kompanse siroz grubunda nesfatin-1 düzeyleri an lamlı olarak yüksek bulundu p0,01. Sirozlu hastalar Child-Pugh evrelerine ve MELD skorlarına göre sınıflandırıldığında bu gru plar ile nesfatin-1 düzeyleri arasında anlamlı bir ilişki saptanmadı. Sonuç: Sirozlu hastalarda kompanze halin sürdürülmesinde nes fatin-1in antioksidan, antiinflamatuar ve antiapoptotik etkileri olabilir. Dekompanse sirozda nesfatin-1 düzeylerinin düşük olması savunma mekanizması ve yetersiz üretimden kaynaklanabilir.

Makale detayları

THE RELATION OF SERUM NESFATIN-1 LEVELS WITH DISEASE SEVERITY AND COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS

Yazarlar:

Özlem Kandemir Alibakan | Hasan Eruzun | İlkim Deniz Toprak | Uğur Yılmaz | Mehmet Alptekin Acar | İpek Bilge Aslan | Merve Polat Onmaz | Yasemin Gökden | Yücel Arman | Tufan Tükek

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.209-214

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001330648

pISSN:

1305-6441

Nesfatin-1

liver

cirrhosis

decompensation

anti-in f lammatory

antioxidantNesfatin-1

karaciğer

siroz

dekompansas yon

antienflamatuvar

antioksidan

Sayı

Makale detayları

Yazarlar: Özlem Kandemir Alibakan | Hasan Eruzun | İlkim Deniz Toprak | Uğur Yılmaz | Mehmet Alptekin Acar | İpek Bilge Aslan | Merve Polat Onmaz | Yasemin Gökden | Yücel Arman | Tufan Tükek

Yayıncı: Istanbul University

Ana Başlıklar: Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi: İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.209-214

Belge Tipi: Makale

Yayın Tarihi: 7/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001330648

pISSN: 1305-6441

Sayı

Yazarlar:

Özlem Kandemir Alibakan | Hasan Eruzun | İlkim Deniz Toprak | Uğur Yılmaz | Mehmet Alptekin Acar | İpek Bilge Aslan | Merve Polat Onmaz | Yasemin Gökden | Yücel Arman | Tufan Tükek

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.209-214

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001330648

pISSN:

1305-6441